CGON — CG Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- $1.70bn
- $962.97m
- $1.14m
- 51
- 14
- 14
- 15
Annual cashflow statement for CG Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -12.8 | -35.4 | -48.6 | -88 |
| Depreciation | ||||
| Non-Cash Items | 1.14 | 1.19 | -0.528 | 6.39 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -1.97 | 4.44 | 3.44 | 2.91 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Cash from Operating Activities | -13.7 | -29.8 | -45.7 | -78.7 |
| Capital Expenditures | -0.097 | -0.014 | — | -0.234 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | -55.3 | -121 | -301 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -0.097 | -55.4 | -121 | -301 |
| Financing Cash Flow Items | — | — | -3.42 | -3.42 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 15.4 | 120 | 87 | 628 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 1.7 | 34.5 | -79.9 | 249 |